Recommended #1 by families and OB/GYNs, Cord Blood Registry® (CBR®) is the world’s largest and most experienced newborn stem cell company. As part of our commitment to advancing the clinical applications of newborn stem cells, we have helped over 600 families use their cord blood samples for current and investigational treatments.
Not only are cord blood stem cells used to treat over 80 conditions today in transplant medicine, newborn stem cells are also being researched in over 500 clinical trials to help in regenerative medicine, which aims to restore or establish normal functioning in the body.
For 30+ years, cord blood has been used to help tens of thousands of people worldwide. Cord blood is a source of stem cells that is currently being used in transplant medicine to replace damaged blood and immune systems with healthy cells. It been proven to treat some blood disorders, cancers, immune disorders and metabolic disorders.
Besides their use in transplant medicine, newborn stem cells are also being studied in 500+ clinical trials for regenerative medicine uses. Regenerative medicine is an area of science that aims to restore or establish normal function in the body. Basically, it involves repairing damaged cells.
Over 80% of newborn stem cell units released from CBR have been for regenerative medicine clinical trials. Stories from CBR clients Abigail and Grace demonstrate some of the potential future uses of newborn stem cells.
CBR is honored to be able to help these families and more, who have used their stem cells to overcome some of life’s biggest obstacles. The greatest hope is that groundbreaking research with cord blood stem cells can help children with serious conditions in a new way. In fact, stem cells saved with CBR are now being accessed by a new family for current and experimental treatments averaging every week. And as the science develops, so do the possibilities.
The use of cord blood is determined by the treating physician and is influenced by many factors, including the patient’s medical condition, the characteristics of the sample, and whether the cord blood should come from the patient or an appropriately matched donor. Cord blood has established uses in transplant medicine; however, its use in regenerative medicine is still being researched. There is no guarantee that potential medical applications being studied in the laboratory or clinical trials will become available.
Cord tissue use is still in early research stages, and there is no guarantee that treatments using cord tissue will be available in the future. Cord tissue is stored whole. Additional processing prior to use will be required to extract and prepare any of the multiple cell types from cryopreserved cord tissue. Cbr Systems, Inc.’s activities for New York State residents are limited to collection of umbilical cord tissue and long-term storage of umbilical cord–derived stem cells. Cbr Systems, Inc.’s possession of a New York State license for such collection and long-term storage does not indicate approval or endorsement of possible future uses or future suitability of these cells.